Kyntra Bio, Inc. (KYNB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kyntra Bio, Inc. (KYNB) has a cash flow conversion efficiency ratio of 0.490x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.99 Million) by net assets ($-8.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Kyntra Bio, Inc. market capitalisation for the company's overall valuation and market capitalisation.
Kyntra Bio, Inc. - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Kyntra Bio, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Kyntra Bio, Inc. (KYNB) share price today for real-time trading data and today's change.
Kyntra Bio, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kyntra Bio, Inc. ranked by their cash flow conversion efficiency. Review KYNB free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fidelity European Values
LSE:FEV
|
0.003x |
|
Atec T& Co. Ltd
KQ:224110
|
-0.026x |
|
SFD SA ZY -10
F:7PQ
|
0.072x |
|
Victory New Materials Ltd Co
TW:1340
|
0.004x |
|
Proximar Seafood AS
OL:PROXI
|
-0.204x |
|
PSQ Holdings Inc.
NYSE:PSQH
|
-0.496x |
|
Nordic Iron Ore
ST:NIO
|
0.002x |
|
Aquarius Engines AM Ltd
TA:AQUA
|
-32.231x |
Annual Cash Flow Conversion Efficiency for Kyntra Bio, Inc. (2012–2025)
The table below shows the annual cash flow conversion efficiency of Kyntra Bio, Inc. from 2012 to 2025. Also see KYNB total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.47 Million | $-4.77 Million | -1.067x | -241.96% |
| 2024-12-31 | $-183.63 Million | $-138.00 Million | 0.751x | -61.31% |
| 2023-12-31 | $-162.20 Million | $-315.02 Million | 1.942x | -98.03% |
| 2022-12-31 | $-1.48 Million | $-145.93 Million | 98.603x | +27572.66% |
| 2021-12-31 | $229.11 Million | $-82.23 Million | -0.359x | -294.16% |
| 2020-12-31 | $441.45 Million | $81.60 Million | 0.185x | +225.75% |
| 2019-12-31 | $535.41 Million | $-78.70 Million | -0.147x | -2.02% |
| 2018-12-31 | $528.47 Million | $-76.14 Million | -0.144x | -26.17% |
| 2017-12-31 | $582.45 Million | $-66.51 Million | -0.114x | -381.33% |
| 2016-12-31 | $175.11 Million | $7.11 Million | 0.041x | +143.02% |
| 2015-12-31 | $196.82 Million | $-18.57 Million | -0.094x | -201.31% |
| 2014-12-31 | $240.68 Million | $22.41 Million | 0.093x | -61.34% |
| 2013-12-31 | $107.60 Million | $25.92 Million | 0.241x | +625.07% |
| 2012-12-31 | $122.18 Million | $-5.61 Million | -0.046x | -- |
About Kyntra Bio, Inc.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible fact… Read more